Although evidence have clearly proved that intravitreal injection of vascular endothelial growth factor antagonists prevents vision loss and may even improve visual acuity in patients with neovascular AMD, a significant percentage of patients continue to lose visual acuity. Moreover, monthly intravitreal injections represent a burden for society as well as the caregiver. Combination therapy with either topical 0.1% pranoprofen or nutraceutical support with AREDS2 formula plus omega-3 might act synergistically with intravitreal injection, offering valuable therapeutic support to aflibercept injections in patients requiring long-term treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
monthly intravitreal injections
0.1% pranoprofen 3 times a day topical eye drops administration
daily supplementation of nutraceutical tablets containing the AREDS2 formulation
Central Retinal Thickness (microns)
Optical Coherence Tomography will be used to assess central retinal thickness.
Time frame: 12-month
Visual Acuity (LogMAR)
ETDRS charts will be used to assess best corrected visual acuity
Time frame: 12-month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.